Status
Conditions
Treatments
About
The investigator's purpose is to study the population pharmacokinetics of paracatamol and ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of dosage individualization.
Full description
The investigator's purpose is to study the population pharmacokinetics of paracatamol and ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of dosage individualization. In this study, the investigator will detect drug concentration in plasma and other clinical test to construct population pharmacokinetic models.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
500 participants in 1 patient group
Loading...
Central trial contact
Wei Zhao, Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal